| Miss Yi-ping Wen, NP | |
|
1500 Duarte Rd, Duarte, CA 91010-3012 | |
| (626) 256-4673 | |
| Not Available |
| Full Name | Miss Yi-ping Wen |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 14 Years |
| Location | 1500 Duarte Rd, Duarte, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093947616 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 20586 (California) | Secondary |
| 363L00000X | Nurse Practitioner | 20586 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| City Of Hope Medical Foundation | 3779751656 | 686 |
News Archive
Golden Meditech Holdings Limited, mainland China's leading integrated healthcare enterprise, is pleased to announce today that the Company has made an application to the Taiwan Stock Exchange and the Taiwan Central Bank for the offering and listing of up to 90 million units of Taiwan Depositary Receipts equivalent to no more than 180 million shares of the Group).
Year-old changes to the system that distributes deceased donor kidneys nationwide have significantly boosted transplantation rates for black and Hispanic patients on waiting lists, reducing racial disparities inherent in the previous allocation formula used for decades, according to results of research led by a Johns Hopkins transplant surgeon.
Menstrual dysfunction is more prevalent in young Finnish athletes than it is among non-athletes of a similar age, but athletes experience less body weight dissatisfaction than non-athletes do.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.
› Verified 3 days ago
| Entity Name | Sierra Madre Community Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902951825 PECOS PAC ID: 8729049663 Enrollment ID: O20041022001121 |
News Archive
Golden Meditech Holdings Limited, mainland China's leading integrated healthcare enterprise, is pleased to announce today that the Company has made an application to the Taiwan Stock Exchange and the Taiwan Central Bank for the offering and listing of up to 90 million units of Taiwan Depositary Receipts equivalent to no more than 180 million shares of the Group).
Year-old changes to the system that distributes deceased donor kidneys nationwide have significantly boosted transplantation rates for black and Hispanic patients on waiting lists, reducing racial disparities inherent in the previous allocation formula used for decades, according to results of research led by a Johns Hopkins transplant surgeon.
Menstrual dysfunction is more prevalent in young Finnish athletes than it is among non-athletes of a similar age, but athletes experience less body weight dissatisfaction than non-athletes do.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.
› Verified 3 days ago
| Entity Name | City Of Hope Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871886366 PECOS PAC ID: 3779751656 Enrollment ID: O20110720000244 |
News Archive
Golden Meditech Holdings Limited, mainland China's leading integrated healthcare enterprise, is pleased to announce today that the Company has made an application to the Taiwan Stock Exchange and the Taiwan Central Bank for the offering and listing of up to 90 million units of Taiwan Depositary Receipts equivalent to no more than 180 million shares of the Group).
Year-old changes to the system that distributes deceased donor kidneys nationwide have significantly boosted transplantation rates for black and Hispanic patients on waiting lists, reducing racial disparities inherent in the previous allocation formula used for decades, according to results of research led by a Johns Hopkins transplant surgeon.
Menstrual dysfunction is more prevalent in young Finnish athletes than it is among non-athletes of a similar age, but athletes experience less body weight dissatisfaction than non-athletes do.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Yi-ping Wen, NP Po Box 512185, Los Angeles, CA 90051-0185 Ph: (626) 256-4673 | Miss Yi-ping Wen, NP 1500 Duarte Rd, Duarte, CA 91010-3012 Ph: (626) 256-4673 |
News Archive
Golden Meditech Holdings Limited, mainland China's leading integrated healthcare enterprise, is pleased to announce today that the Company has made an application to the Taiwan Stock Exchange and the Taiwan Central Bank for the offering and listing of up to 90 million units of Taiwan Depositary Receipts equivalent to no more than 180 million shares of the Group).
Year-old changes to the system that distributes deceased donor kidneys nationwide have significantly boosted transplantation rates for black and Hispanic patients on waiting lists, reducing racial disparities inherent in the previous allocation formula used for decades, according to results of research led by a Johns Hopkins transplant surgeon.
Menstrual dysfunction is more prevalent in young Finnish athletes than it is among non-athletes of a similar age, but athletes experience less body weight dissatisfaction than non-athletes do.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.
› Verified 3 days ago
Miss Janice Mae Villegas, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2236 Park Rose Ave, Duarte, CA 91010 Phone: 626-475-4663 | |
Mrs. Erica H Chin, RN, NP, MS Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1500 East Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 Fax: 626-471-7155 | |
Maria Elena Dela Rosa, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 | |
Mrs. Denise Lee Falardeau, N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1500 Duarte Rd, Machris 2101, Duarte, CA 91010 Phone: 626-471-9200 Fax: 626-218-0188 | |
Tim Nguyen, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 | |
Miss Gabriela Claudia Medrano, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 | |
Rhodelynn Bonner, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 Fax: 626-301-8256 |